Changes in endothelial dysfunction and associated cardiovascular disease morbidity markers in GH-IGF axis pathology

American Journal of Cardiovascular Drugs

Volumn 9, Issue 6, 2009, Pages 371-381

  Graham, Michael R ^a,b   Evans, Peter ^c   Thomas, Non Eleri ^d   Davies, Bruce ^b   Baker, Julien S ^b,e  

^a NEWMAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLAMORGAN   (United Kingdom)

^c ROYAL GWENT HOSPITAL   (United Kingdom)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FIBRINOGEN; GROWTH HORMONE; HOMOCYSTEINE; HUMAN GROWTH HORMONE; INTERLEUKIN 6; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PROPRANOLOL; ROSIGLITAZONE; SOMATOMEDIN; SOMATOMEDIN C;

ACROMEGALY; ADENOHYPOPHYSIS; ARTERIAL STIFFNESS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; DRUG DOSE ESCALATION; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LOW DRUG DOSE; MORBIDITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PULSE WAVE; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

AGING; ARTERIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; MODELS, BIOLOGICAL; PULSE; RECOMBINANT PROTEINS;

EID: 71149111194     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11312100-000000000-00000     Document Type: Review

References (127)

1. Cohn JN, Finkelstein S, McVeigh G, et al. Non-invasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995; 26: 503-508
2. Brinton TJ, Kailasam MT, Wu RA, et al. Arterial compliance by cuff sphygmomanometer: Application to hypertension and early changes in subjects at genetic risk. Hypertension 1996; 28: 599-603
3. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995; 26: 485-490
4. O'Rourke MF. Wave travel and reflection in the arterial system. J Hypertens 1999; 17: 45-47
5. O'Rourke MF, PaucaA, Jiang XJ. Pulse wave analysis. Br J Clin Pharm 2001; 51: 507-522
6. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse-wave analysis: Clinical evaluation of a non-invasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002; 22: 147-152
7. O'Rourke MF. Arterial mechanics and wave reflection with antihypertensive therapy. J Hypertens Suppl 1992; 10: 43-49
8. Kelly RP, Millasseau SC, Ritter JM, et al. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension 2001; 37: 1429-1433
9. Wilkinson IB, MacCallum H, Hupperetz PC, et al. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and nor-adrenaline in man. J Physiol 2001; 530: 541-550
10. Westerbacka J, Wilkinson I, Cockcroft J, et al. Diminished wave reflection in the aorta: A novel physiological action of insulin on large blood vessels. Hypertension 1999; 33: 1118-1122
11. Kinlay S, Creager MA, FukumotoM, et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001; 38: 1049-1053
12. Stewart AD, Millasseau SC, Kearney MT, et al. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42: 915-918
13. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202-1207
14. Wilkinson IB, Quasem A, McEniery CM, et al. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105: 213-217
15. Murray RD, Wieringa GE, Lissett CA, et al. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol (Oxf) 2002; 56: 525-532
16. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: A randomized, placebo-controlled study. J Clin EndocrinolMetab 2008; 93: 2063-2071
17. Ghio L, Damiani B, Garavaglia R, et al. Lipid profile during rhGH therapy in pediatric renal transplant patients. Pediatr Transplant 2002; 6: 127-131
18. Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188-1192
19. Pfeifer M, Verhovec R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 453-457
20. Cuneo RC, Salomon F, Wiles CM, et al. Skeletal muscle performance in adults with growth hormone-deficiency. Horm Res 1990; 33: 55-60
21. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. I: Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688-694
22. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II: Effects on exercise performance. J Appl Physiol 1991; 70: 695-700
23. Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: Defects in glucose utililization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555-564
24. Hennessey JV, Chromiak JA, DellaVentura S, et al. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 2001; 49: 852-858
25. Shulman DI, Root AW, Diamond FB, et al. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. J Clin Endocrinol Metab 2003; 88: 4095-4099
26. Graham MR, Baker JS, Evans P, et al. Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users. Growth Horm IGF Res 2007; 17: 328-335
27. Evans WJ, Kotler DP, Staszewski S, et al. Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART. AIDS Read 2005; 15: 301-303
28. van der Klaauw A, Bax J, Bleeker G, et al. Cardiac manifestations of growth hormone deficiency after treatment for acromegaly: A comparison to patients with biochemical remission and controls. Eur J Endocrinol 2008; 159: 705-712
29. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991; 12: 424-449
30. Melmed S. Acromegaly. N Engl J Med 2006; 354 (14): 2558-2573
31. Toogood AA. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm Res 2003; 60: 105-111
32. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814-821
33. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993; 74: 237-244
34. Le Roith D, Scavo L, Butler A.What is the role of circulating IGF-I? Trends Endocrinol Metab 2001; 12: 48-52
35. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508
36. Milani D, Carmichael JD, Welkowitz J, et al. Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 2004; 89: 2271-2274
37. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable. Growth Horm IGF Res 2005; 15: 19-27
38. Mauras N, AttieKM,Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment ofGH-deficient patients in puberty increases nearfinal height: A randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85: 3653-3660
39. O'Neal D, Few FL, Sikaris K, et al. Low density lipoprotein particle size in hypopituitary adults receiving conventional growth hormone replacement therapy. J Clin Endocrinol Metab 1996; 81: 2448-2454
40. Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; I: 1221-1225
41. Salomon F, Cuneo RC, Hesp R, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803
42. Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-I in growth hormone deficient adult patients on growth hormone replacement therapy: Analysis of the German KIMS data and the Study of Health in Pomerania (SHIP). Acta Paediatr Eur J Endocrinol 2008; 160 (1): 17-24
43. Gotherstrom G, Bengtsson BA, Bosaeus I, et al. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007; 92: 1442-1445
44. Laursen T, Jørgensen JO, Christiansen JS. The management of adult growth hormone deficiency syndrome. Expert Opin Pharmacother 2008; 9: 2435-2450
45. Schauster AC, Geletko SM, Mikolich DJ. Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. Pharmacotherapy 2000; 20: 1129-1134
46. Zhang MM, Wu XT, Zhou Y, et al. Short-term application of low-dose growth hormone in surgical patients: Effects on nitrogen balance and blood glucose. World J Gastroenterol 2007; 21: 452-456
47. Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: Comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008; 9: 254-268
48. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-1676
49. Hoffman DM, Crampton I, Sernia C. Short term growth hormone (GH) treatment of GH deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab 1996; 81: 1123-1128
50. Jeschke MG, Finnerty CC, Kulp GA, et al. Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr Crit Care Med 2008; 9: 209-216
51. Merola B, Longobardi S, Sofia M, et al. Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: Effect of 12 months' growth hormone replacement therapy. Eur J Endocrinol 1996; 135: 553-558
52. Meineri I, Andreani O, Sanna R, et al. Effect of low-dosage recombinant human growth hormone therapy on pulmonary function in hypopituitary patients with adult-onset growth hormone deficiency. J Endocrinol Invest 1998; 21: 423-427 (Pubitemid 28439000)
53. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: Cardiovascular implications. Blood Press 2005; 14: 227-232
54. Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 2003; 14: 25-39
55. Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985; 312: 9-17
56. Thorner MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest 1982; 70: 965-977
57. Bramwell JC, Hill AV. The velocity of the pulse wave in man. Proc R Soc Lond B Biol Sci 1922; 93: 298-306
58. Lantelme P,Mestre C, Lievre M, et al. Heart rate: An important confounder of pulse wave velocity assessment. Hypertension 2002; 39: 1083-1087
59. Giannattasio C, Vincenti A, Failla M, et al. Effects of heart rate changes on arterial distensibility in humans. Hypertension 2003; 42: 253-256
60. Lehmann ED, Hopkins KD, Rawesh A, et al. Relation between number of cardiovascular risk factors/events and non-invasive Doppler ultrasound assessments of aortic compliance. Hypertension 1998; 32: 565-569
61. Bramwell JC,Hill AV, McSwiney BA. The velocity of the pulse wave in man in relation to age as measured by the hot wire sphygmograph. Heart 1923; 10: 233-255
62. Lehmann ED, Watts GF, Gosling RG. Aortic distensibility and hypercholesterolaemia. Lancet 1992; 340: 1171-1172
63. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med 1992; 9: 114-119
64. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993; 88: 1456-1462
65. Tomiyama H, Yamashina A, Arai T, et al. Influences of age and gender on results of non-invasive brachial-ankle pulse wave velocity measurement/ a survey of 12,517 subjects. Atherosclerosis 2003; 166: 303-309
66. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241
67. O'Rourke MF, Staessen JA, Vlachopoulos C, et al. Clinical applications of arterial stiffness: Definitions and reference values. Am J Hypert 2002; 15: 426-444
68. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: 1111-1117
69. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15
70. Meaume S, Benetos A, Henry OF, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001; 21: 2046-2050 (Pubitemid 34219760)
71. Hallock P, Benson IC. Studies on the elastic properties of human isolated aorta. J Clin Invest 1937; 16: 595-602
72. Avolio A, Jones D, Tafazzoli-Shadpour M. Quantification of alterations in structure and function of elastin in the arterialmedia. Hypertension 1998; 32: 170-175
73. Greenfield JC, Patel DJ. Relation between pressure and diameter in the ascending aorta of man. Circ Res 1962; 10: 778-781
74. Bank AJ, Wang H, Holte JE, et al. Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus. Circulation 1996; 94: 3263-3270
75. Bank AJ, Kaiser DR, Rajala S, et al. In vivo human brachial artery elastic mechanics: Effects of smooth muscle relaxation. Circulation 1999; 100: 41-47
76. Medley TL, Cole TJ, Gatzka CD, et al. Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. Circulation 2002; 105: 810-815
77. Lajemi M, Gautier S, Poirier O, et al. Endothelin gene variants and aortic and cardiac structure in never-treated hypertensives. Am J Hypertens 2001; 14: 755-760
78. Balkestein EJ, Staessen JA, Wang JG, et al. Carotid and femoral artery stiffness in relation to three candidate genes in a white population. Hypertension 2001; 38: 1190-1197
79. Lajemi M, Labat C, Gautier S, et al. Angiotensin II type I receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19: 407-413
80. Kroeker EJ, Wood EH. Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man. Circ Res 1955; 3: 623-632
81. Rowell LB, Brengelmann GL, Blackmon JR, et al. Disparities between aortic and peripheral pulse pressures induced by upright exercise and vasomotor changes in man. Circulation 1968; 37: 954-964
82. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992; 70: 851-858
83. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142
84. Förstermann U, Nakane M, Tracey WR, et al. Isoforms of nitric oxide synthase: Functions in the cardiovascular system. Eur Heart J 1993; 14: 10-15
85. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Ann Rev Pharmacol Toxicol 1984; 24: 175-197
86. Cocks TM, Angus JA, Campbell JH, et al. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 1985; 123: 310-320
87. Newby AC, Henderson AH. Stimulus-secretion coupling in vascular endothelial cells. Ann Rev Physiol 1990; 52: 661-674
88. Pohl U, Holtz J, Busse R, et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8: 37-47
89. Busse R, Pohl U. Fluid shear-stress-dependent stimulation of endothelial cell autacoid release: mechanisms and significance for the control of vascular tone. In: Frangos JA, Ives CL, editors. Physical forces and the mammalian cell. Orlando (FL): Academic Press, 1993: 223-248
90. Meredith IT, Currie KE, Anderson TJ, et al. Post ischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 1996; 270: 1435-1440
91. Ramsey MW, Goodfellow J, Jones CJH, et al. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 1995; 92: 3212-3219
92. Yaginuma T, Avolio A, O'Rourke MF. Effects of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Circ Res 1986; 20: 153-160
93. Joannides R, Richard V, Haefeli WE, et al. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension 1997; 30: 1465-1470
94. Evans LM, Davies JS, Anderson RA, et al. The effect of GH replacement on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000; 142: 254-262
95. Evans LM, Davies JS, Goodfellow J, et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol 1999; 50: 457-464
96. Pfeifer M, Verhovec M, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 453-457
97. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: A randomized, double-blind, placebo-controlled study. Clin Endocrinol 2002; 56: 493-501
98. Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 90-95
99. Lilien MR, Schroder CH, Levtchenko EN, et al. Growth hormone therapy influences endothelial function in children with renal failure. Pediatr Nephrol 2004; 19: 785-789
100. McCallum RW, Sainsbury CA, Spiers A, et al. Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf) 2005; 62: 473-479
101. Smith JC, Lane H, Davies N, et al. The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab 2003; 88: 2556-2561
102. Fryburg DA, NG-monomethyl-l-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-I. Possible role of nitric oxide in muscle protein synthesis. J Clin Invest 1996; 97:1319-1328
103. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
104. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397
105. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: A randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-122
106. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002; 87: 1692-1699
107. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419
108. Leonsson M, Hulthe J, Johannsson G, et al. Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intimamedia thickness. Clin Endocrinol (Oxf) 2003; 59: 242-250
109. Eden S, Wilklund O, Oscarsson J, et al. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296-301
110. Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep 2006; 8: 111-115
111. Graham MR, Baker JS, Evans P, et al. Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users. Growth Horm IGF Res 2007; 17: 201-209
112. Vincent AM, Maiese K. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp Cell Res 1999; 246: 290-300 (Pubitemid 29393990)
113. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 2004; 101: 8491-8496
114. Yorek M, Leeney E, Dunlap J, et al. Effect of fatty acid composition on insulin and IGF-I binding in retinoblastoma cells. Invest Ophthalmol Vis Sci 1989; 30: 2087-2092
115. Bazan NG. Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005; 15: 159-166
116. Linseman DA, Phelps RA, Bouchard RJ, et al. Insulin-like growth factor-I blocks Bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signaling in cerebellar granule neurons. J Neurosci 2002; 22: 9287-9297
117. Leinninger GM, Backus C, Uhler MD, et al. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J 2004; 18: 1544-1546
118. Ceda GP, Dall'Aglio E, Maggio M, et al. Clinical implications of the reduced activity of the GH-IGF-I axis in older men. J Endocrinol Invest 2005; 28: 96-100
119. Sutton J, Lazarus L. Growth hormone in exercise: Comparison of physiological and pharmacological stimuli. J Appl Physiol 1976; 41: 523-527
120. Felsing NE, Brasel JA, Cooper DM. Effect of low and high intensity exercise on circulating growth hormone in men. J Clin Endocrinol Metab 1992; 75: 157-162
121. Eliakim A, Nemet D, Zaldivar F, et al. Reduced exercise-associated response of the GH-IGF-I axis and catecholamines in obese children and adolescents. J Appl Physiol 2006; 100: 1630-1637
122. Svensson J, Bengtsson BA, Taskinen MR. A nine-month, placebo-controlled study of the effects of GH treatment on lipoproteins and LDL size in abdominally obese men. Growth Horm IGF Res 2000; 10: 118-126
123. NorrelundH,Nair KS,Nielsen S, et al. The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone. J Clin Endocrinol Metab 2003; 88: 4371-4378
124. Liu W, Thomas SG, Asa SL, et al. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab 2003; 88: 5490-5496
125. Graham MR, Baker JS, Evans P, et al. Physical effects of short term rhGH administration in abstinent steroid dependency. Horm Res 2008; 69: 343-354
126. Takano H, Morita T, Iida H, et al. Hemodynamic and hormonal responses to a short-term low-intensity resistance exercise with the reduction of muscle blood flow. Eur J Appl Physiol 2005; 95: 65-73
127. Liu H, Bravata DM, Olkin I, et al. Systematic review: The safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 16: 104-115